Anti-TROP2 Antibody
Based on 1 Customer Validation
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity : 96.44%
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Anti-TROP2 Antibody (0.1-10 μg/mL; overnight) induces mitotic arrest in Trop-2-positive BxPC3 pancreatic cancer cells[1].
Anti-TROP2 Antibody (0.004-267 nM; 4 days) potently kills a variety of Trop-2-expressing human tumor cell lines, with an IC50 value reaching the sub-nanomolar range[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BxPC3 pancreatic cancer cells, SW620 colon cancer cells
-
Concentration:0.1, 1, 10 μg/mL
-
Incubation Time:overnight
-
Result:Induced a dramatic increase in phosphorylated histone H3-positive cells in Trop-2-positive BxPC3 cells at 0.1 μg/mL, indicating widespread mitotic arrest.
Caused BxPC3 cells to detach from slides due to cell death at 10 μg/mL.
Showed no increase in phosphorylated histone H3 staining in Trop-2-negative SW620 cells at 10 μg/mL compared to untreated cells.
-
Cell Line:A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3, SW620
-
Concentration:0.004-267 nM
-
Incubation Time:4 days
-
Result:Potently killed most Trop-2-expressing cell lines (A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3 cells), with IC50 values of 0.202, 0.507, 0.56, 0.674, 0.533, 0.633, 1.92, 0.779, 0.773, 5.06, 0.42 nM.
Showed no cytotoxicity toward Trop-2-negative SW620 cells, despite free PF-06380101 payload being active against SW620 cells with an IC50 of 0.305 nM.
In Vivo
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus administration/once every 2 weeks; 2 doses total) induces regression of mouse Pan0123 pancreatic PDX xenograft tumors[1].
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus) induces regression and eradication of Ova196756 ovarian PDX xenograft tumors in mice[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus administration) induces sustained regression of TROP2 LG0476 lung cancer PDX xenografts in mice[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus; repeated administration 63 days after the first dose) induces long-term regression of large CTG-1017 triple-negative breast cancer PDX xenografts in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17/SCID (female, 5-6 weeks old, pancreatic cancer xenograft with 2 million BxPC3 cells implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced tumor regression at 1.5 mg/kg and 3.0 mg/kg doses.
Inhibited tumor growth at 0.75 mg/kg dose compared to controls.
-
Animal Model:CB17/SCID (female, pancreatic cancer PDX xenograft with 1-2 mm3 Pan0123 fragments implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection/i.v.; every 2 weeks; 2 total doses
-
Result:Induced tumor regression at all tested single doses, with the most persistent regression seen at higher doses.
-
Animal Model:CB17/SCID (female, ovarian cancer PDX xenograft with 1-2 mm3 Ova196756 fragments implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced tumor regression at all tested single doses.
Induced more persistent regression and tumor eradication at doses ≥1.5 mg/kg.
-
Animal Model:CB17/SCID (female, lung cancer PDX xenograft with 1-2 mm3 LG0476 fragments implanted subcutaneously)[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced sustained tumor regression.
Showed superior efficacy over gemcitabine treatment (tumor regrew sooner) and paclitaxel treatment (only partial growth inhibition).
-
Animal Model:CB17/SCID (female, triple-negative breast cancer PDX xenograft with 1-2 mm3 CTG-1017 fragments implanted subcutaneously)[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; single bolus injection; repeated 63 days after first dose
-
Result:Induced tumor regression lasting more than 60 days with the first single dose.
Induced another long-duration tumor regression after retreatment of regrown tumors.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Anti-TROP2 Antibody]
-
Synonyms
RN927C antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-TROP2 Antibody Related Classifications
HY-P991372 Related Classifications
Powered by Bioz